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Preamble
A number of studies conducted both in heart failure with reduced
and with preserved ejection fraction were presented and published
in 2015. Most of them were neutral and did not demonstrate any
benefit on outcomes of the drugs/procedures tested. Nevertheless,
they bring important new information on the search for new drugs
or procedures in the management of heart failure.
Adaptive servo-ventilation in heart
failure and central sleep apnoea: is
it harmful?
Sleep-disordered breathing is common in patients with heart failure
and reduced ejection fraction. Two different types of abnormality
have been described: obstructive sleep apnoea and central sleep ap-
noea. The prevalence of central sleep apnoea, which may manifest as
Cheynes–Stokes respiration, increases with the severity of heart
failure and this condition is associated with poor outcomes.
The purpose of SERVE-HF was to assess the effects of adaptive
servo-ventilation (ASV) that delivers servo-controlled inspiratory
pressure support on top of expiratory positive airway pressure in
patients with moderate to severe heart failure and an ejection of
,45% who had predominantly central sleep apnoea.1 In this trial,
1325 patients were enrolled and randomized to ASV (666) or to
control therapy (659). Patients were predominantly in New York
Heart Association Class III and were well treated by recommended
therapies. The incidence of the primary endpoint made of the com-
posite of death of any cause, lifesaving cardiovascular intervention,
or unplanned hospitalization for heart failure did not differ signifi-
cantly between the two groups (HR ¼ 1.13; 95% CI, 0.97–1.31;
P ¼ 0.10). The surprise was the observation of a significant increase
of all-cause mortality (HR ¼ 1.28; 95% CI, 1.06–1.55; P ¼ 0.01) and
of cardiovascular mortality (HR ¼ 1.34; 95% CI, 1.09–1.65; P ¼
0.006) in the ASV group. The findings of SERVE-HF contrast with
evidence from earlier smaller studies that suggested an improve-
ment in left ventricular function, quality of life, and mortality.
One potential explanation for the increase in cardiovascular
mortality is that central sleep apnoea may be a compensatory
mechanism, and therefore reducing this adaptive respiratory pat-
tern by ASV may be detrimental. The other explanation put for-
ward by Cowie et al. is that the application of positive airway
pressure may impair cardiac function, in particular, in patients
with low pulmonary capillary wedge pressure. The timing of death
and whether the fatal events occurred while patients were under
ASV will be therefore important to determine the potential mech-
anism of harm.
One important implication of the negative results of SERVE-HF is
that this procedure should not be recommended anymore for pa-
tients with heart failure and reduced ejection fraction and central
sleep apnoea and stopped in those patients currently treated by
this procedure. This, however, does not apply to obstructive sleep
apnoea.
Whether other techniques diminishing Cheynes–Stokes respir-
ation such as phrenic nerve stimulation are beneficial or harmful re-
mains an open question until the results of the ongoing trial testing
phrenic nerve stimulation are available.
Glucose-lowering agents and risk of
heart failure: new and reassuring
results
Dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors) have been used
for several years in the management of type 2 diabetes mellitus. In
2013, the publication of SAVOR-TIMI 53 raised concern on the
safety of this class regarding the occurrence of heart failure events.2
This large outcome trial including patients with diabetes mellitus and
a previous cardiovascular event or at high cardiovascular risk
showed that the overall cardiovascular safety of saxagliptin was
good, except a 27% increase in the risk of the first event worsening
heart failure hospitalization. There was no biological plausible ex-
planation for this observation. Nevertheless, this raised concern
on potential harm all the more as another trial EXAMINE con-
ducted in patients with diabetes mellitus and presenting with an
acute coronary syndrome suggested a non-significant signal for in-
creased risk of heart failure with another DPP4 inhibitor, alogliptin
(Table 1).3
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The publication of TECOS, another mega trial including 14 671
patients was therefore long awaited.4 Patients included had type 2
diabetes mellitus, were 50 years of age or more, and had an estab-
lished cardiovascular disease and a baseline HbA1C of 6.5–8%.
They were randomized to either the DPP4 inhibitor sitagliptin or
to control treatment.
After 3 years of follow-up, no difference was observed in the oc-
currence of the composite endpoint of cardiovascular mortality,
non-fatal myocardial infarction, non-fatal stroke, or hospitalization
for unstable angina (HR ¼ 0.98; 95% CI, 0.88–1.09; P, 0.001 for
non-inferiority). Importantly, the incidence of heart failure was simi-
lar in the two arms with a hazard ratio of 1.00 (95% CI, 0.83–1.20;
P ¼ 0.98). The explanation for the differential effect of sitagliptin and
of saxagliptin on heart failure events remain uncertain: differences in
populations enrolled in the two trials are unlikely to play a role since
the clinical profile of the patients were rather similar. Differences in
affinity of the two inhibitors to the various substrates of DPP4 are a
potential explanation. Finally, the play of chance cannot be excluded
in this very large trial.
Whatever the underlying explanation, the results of this large
outcome trial in type 2 diabetes mellitus rule out a class effect of
DPP4 inhibitors on heart failure events and are therefore reassuring
regarding the safety of sitagliptin in patients with pre-existing heart
failure or at high risk of heart failure.
Another trial, EMPA-REG OUTCOME, tested two doses of an in-
hibitor of sodium-glucose co-transporter 2, empagliflozin vs. pla-
cebo in 7020 patients with type 2 diabetes at high cardiovascular
risk.5 After a median observation time of 3.1 years, the primary out-
come made of death from cardiovascular causes, non-fatal myocar-
dial infarction, or non-fatal stroke was significantly reduced by 14%
in the pooled empagliflozin group. Interestingly, hospitalizations for
heart failure and the composite of hospitalization for heart failure or
death from cardiovascular causes, two secondary endpoints, were
also significantly reduced by 35% (P ¼ 0.002) and 34% (P, 0.01),
respectively, suggesting that this new anti-diabetic agent added to
standard therapy is not only safe but also beneficial for the preven-
tion of heart failure hospitalizations in type 2 diabetes mellitus.
Management of heart failure
with preserved ejection fraction
remains a clinical dilemma
The medical management of heart failure with preserved ejection
fraction (HFpEF) remains challenging, and no drug has demonstrated
a clear benefit on morbidity and mortality in this population (Figure 1).
The SUPPORT trial examined whether an additive treatment
with an angiotensin receptor blocker, olmesartan, reduces the mor-
tality and morbidity in hypertensive patients with chronic heart fail-
ure treated with angiotensin-converting enzyme (ACE) inhibitors,
beta blockers, or both. In this prospective randomized open-label
study, 1147 patients were enrolled.6 Mean ejection fraction was
54%. During a median follow-up of 4.4 years, there was no statistical
difference in the occurrence of the primary outcome made of all-
cause death, non-fatal myocardial infarction, non-fatal stroke, and
hospitalization for worsening heart failure between the two groups
(HR ¼ 1.18; 95% CI, 0.96–1.46; P ¼ 0.11), whereas a significant in-
crease in worsening renal function was observed. The addition of ol-
mesartan to patients treated by the combination of ACE inhibitors
and beta blockers was, however, associated with a significant in-
crease in the occurrence of the primary endpoint (HR ¼ 1.47;
95% CI, 1.11–1.95; P ¼ 0.006) all-cause death and renal dysfunction.
These findings lead to the conclusion that combination therapy of
ACE inhibitors, angiotensin receptor antagonists, and beta blockers
is not recommended in HFpEF since it is associated with increased
cardiovascular risk and increased risk of renal dysfunction.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Heart failure events in recent trials with glucose-lowering drugs
Study Drug No. of Patients Follow-up (years) Heart failure (HR) hospitalization P-value
SAVOR Saxagliptin 16 492 2.1 1.27 (95% CI, 1.07–1.51) 0.007
EXAMINE Alogliptin 5380 1.5 1.07 (95% CI, 0.79–1.46) 0.66
TECOS Sitagliptin 14 671 3.0 1.00 (95% CI, 0.83–1.20) 0.98
EMPA-REG Empagliflozin 7020 3.1 0.65 (95% CI, 0.50–0.85) 0.002
Figure 1 Kaplan Meier curve for the primary composite end-
point (all cause death, non fatal myocardial infarction, non fatal
stroke and hospitalization for worsening heart failure ) in the over-
all SUPPORT population.6
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In 2013, the RELAX trial conducted in 216 elderly patients with
HFpEF showed the absence of effect of the phosphodiesterase type
5 sildenafil on maximal exercise capacity, 6 min walking distance, clin-
ical status, quality of life, left ventricular remodelling or diastolic func-
tion after 24 weeks of follow-up.7 These results were in contrast with
a previous single centre study that showed benefit on invasively mea-
sured haemodynamics, echocardiographic variables, and quality of life
in patients with pulmonary hypertension related to HFpEF.8
Another just recently published single centre study by Hoender-
mis et al. published in the European Heart Journal, however, casts fur-
ther doubt on the use of sildenafil in HFpEF patients with associated
pulmonary hypertension.9 Fifty-two patients with HFpEF and pre-
dominantly isolated post-capillary pulmonary hypertension were
randomized to sildenafil or placebo. After 24 weeks, sildenafil did
not reduce pulmonary artery pressures and did not improve other
invasive haemodynamic or clinical parameters, thus confirming the
findings of the aforementioned RELAX study that HFpEF patients
with associated pulmonary hypertension do not benefit from treat-
ment with this drug.
The current paradigm of HFpEF is that an abnormal nitric oxide
bioavailability results in decreased cyclic guanylate monophosphate
(cGMP) in the myocytes. One potential explanation of the lack of
benefit from sildenafil is therefore that the defect is more a decrease
in the production of cGMP than a problem of increased degradation
that is inhibited by PDE5 inhibitors such as sildenafil. It will therefore
be interesting to see the results of studies using a soluble guanylate
cyclase (sGC) stimulator, such as riociguat, which is currently under
evaluation. The results of the SOCRATES-REDUCED study, how-
ever, highlight the challenges in moving the concept of modulating
sGC and thereby addressing the relative cGMP deficit forward.10
In SOCRATES-REDUCED, a phase 2 dose-finding study in patients
with heart failure with reduced ejection fraction and worsening
chronic HF, the oral sGC stimulator vericiguat did not meet its pri-
mary endpoint of reducing N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) at 12 weeks when all doses were combined,
but was well tolerated. While subgroup analysis did suggest efficacy
and safety in its 10 mg subgroup, further studies are needed to de-
termine the potential role of this class of drugs for patients with
worsening chronic HF.
The current paradigm that increasing nitric oxide bioavailability
may provide meaningful net clinical benefit was further questioned
by the just recently published results of the multicentre, double-blind,
placebo-controlled Nitrate’s Effect on Activity, Tolerance in Heart
Failure with Preserved Ejection Fraction (NEAT-HFpEF) trial.11
In this National Heart, Lung, and Blood Institute-sponsored trial,
110 patients with heart failure and preserved ejection fraction were
randomly assigned to a 6-week dose-escalation regimen of isosorbide
mononitrate (from 30 to 60 mg to 120 mg once daily) or placebo,
with subsequent crossover to the other group for 6 weeks. Intriguing-
ly, at every tested nitrate dose patients with HFpEF had lower levels of
activity and did not have better quality of life or submaximal exercise
capacity than patients taking placebo. Of note, no interaction be-
tween the subgroups, including by age, sex, heart failure aetiology,
natriuretic peptide levels, or blood pressure, was observed.
It is intriguing to speculate whether other Nitric Oxyde donors
than isosorbide mononitrate, such as inorganic nitrite or nitrate
(which have been shown to increase nitric oxide bioavailability during
exercise), might have yielded more beneficial results under the con-
ditions of the study. This notwithstanding, the somewhat counter-
intuitive findings of NEAT-HFpEF once again highlight the distinct
pathophysiologic differences between HFpEF vs. heart failure with re-
duced ejection fraction (HFrEF). Indeed, since long-acting nitrates im-
prove symptoms in HFrEF, the results of NEAT-HFpEF therefore
suggest that the potential haemodynamic benefits of nitrates are
less likely to come into play under the conditions of increased ven-
tricular systolic and vascular stiffness, autonomic dysfunction, chron-
otropic incompetence, and altered baroreflex sensitivity as they are




Angioedema is a rare but potentially life-threatening side effects of ACE
inhibitors and there is no approved treatment. It is generally related to
the inhibition of the degradation of bradykinin, therefore increasing the
activity of this peptide. A phase 2 study compared the effects of sub-
cutaneous icatiband, a selective bradykinin B2 receptor antagonist to
intravenous prednisolone plus an antihistaminic agent, clemastine, in
27 patients who had ACE-induced angioedema of the upper aerodiges-
tive tract.12 Icatiband induced a complete resolution of symptoms in 8 h
on average compared with 27 h with standard therapy.
These results suggest that the use of a bradykinin receptor antag-
onist allows complete resolution of ACE inhibitors induced angioe-
dema faster than with the standard therapy.
Alcohol consumption and risk
of heart failure
Heavy alcohol consumption is associated with cardiac dysfunction
and eventual alcoholic cardiomyopathy (Figure 2). However, the re-
lationship between moderate alcohol intake and risk of heart failure
is controversial. Self-reported alcohol consumption was assessed in
14 629 participants of the Atherosclerosis Risk in Communities
(ARIC) study without prevalent heart failure at baseline.13 During
an average follow-up of 24 years, incident heart failure occurred
in 1271 men and 1237 women. Men consuming up to 7 drinks a
week (one drink ¼ 14 g of alcohol) had a reduced risk of heart fail-
ure relative to abstainers (HR ¼ 0.80; 95% CI, 0.68–0.94; P ¼
0.006). This ‘protective’ effect was less robust in women (HR ¼
0.84; 95% CI, 0.71–1.00; P ¼ 0.05). In the heavy drinking categories,
the risk of heart failure was not different from abstainers either in
women or in men. These results suggest therefore that modest al-
cohol consumption may be associated with a lower risk of heart
failure.
Gene therapy in chronic heart
failure: disappointment
Cardiac regeneration using gene transfer in the myocardium is a no-
vel approach to the treatment of heart failure. Abnormal calcium
cycling in the cardiomyocyctes is a hall mark of moderate to severe
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heart failure, and one key element is deficient expression and activ-
ity of sarcoplasmic reticulum Ca2+ ATPase type 2a (SERCA2a), the
molecule that pumps calcium from the cytosol to the intracellular
stores, i.e. the sarcoplasmic reticulum. Preclinical studies have
shown that the increased expression of SERCA2a in cardiomyo-
cytes normalizes calcium cycling and that SERCA2a gene transfer
in large animal models can reverse cardiac dysfunction. CUPID 2 en-
rolled 250 patients with severe heart failure who received intracor-
onary either the transgene (123) or placebo (127).14 The primary
endpoint was time to recurrent heart failure-related hospitalizations
and ambulatory worsening heart failure in presence of terminal
events, including all-cause death or transplant. There was no differ-
ence between the active and the conventional arms for the primary
endpoint (HR ¼ 0.93; 95% CI, 0.53–1.65; P ¼ 0.81) or for any of the
secondary endpoints. No safety issue was raised during the trial.
These disappointing results have no clear explanation and are in par-
ticular in contradiction with a previous smaller trial (CUPID), which
suggested that intracoronary injection of SERCA2a transgene was
associated with a dose-dependent beneficial effect on ventricular
function, patient well-being, and biomarkers at 6 and 12 months
and that outcomes were improved at 3 years in the patients treated
with the high dose. Potential explanations for failure include dose of
the transgene, mode of injection, durability of the effect, type of vec-
tor (here an adenovirus) and promoter (cytomegalovirus), or the
target. It is hoped that these negative results will not freeze research
in this area and that different approaches including more cardio spe-
cific promoters, mode of injection, or vectors will be tested to bet-




Chagas’disease is a common parasitic disease in Latin America and is
responsible for the most common form of non-ischaemic
cardiomyopathy in this area. Chagas’cardiomyopathy develops in
25% of patients infected by Trypanosoma cruzi 20–30 years after
the acute infection. The role of trypanocidal therapy at the stage
of Chagas’cardiomyopathy is unproven .The Benznidazole Evalu-
ation for Interrupting Trypanosomiasis (BENEFIT) trial evaluated
the effects on outcomes of oral benznidazole, a trypanocidal agent
vs. placebo in 2854 patients who had evidence of Chagas’cardio-
myopathy.15 The drug was administered for 40–80 days and pa-
tients were followed for a mean of 5.4 years. The primary
outcome was time to death, resuscitated ventricular tachycardia, in-
sertion of a pacemaker or implantable cardioverter-defibrillator,
cardiac transplantation, new heart failure, stroke, or other thrombo-
embolic event. Although trypanocidal therapy with benznidazole
significantly reduced serum parasite detection by polymerase chain
reaction, there was no significant effect on the primary outcome
(HR ¼ 0.93; 95% CI, 0.81–1.07; P ¼ 0.31). Potential explanations
for these negative results include genetic variations of T. cruzi, insuf-
ficient period of observation, and late treatment at a stage of ad-
vanced cardiac disease.
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